Spots Global Cancer Trial Database for Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases

Official Title: Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery: A Randomized Phase II Clinical Trial

Study ID: NCT02387905

Conditions

Metastatic Malignant Neoplasm in the Spine

Metastatic Malignant Solid Neoplasm

Interventions

Management of Therapy Complications

Quality-of-Life Assessment

Questionnaire Administration

Stereotactic Radiosurgery

Study Description

Brief Summary: This randomized phase II trial studies how well cement augmentation works in preventing vertebral body compression fracture following spine stereotactic radiosurgery in patients with solid tumors that have spread to the spine. Spine stereotactic radiosurgery delivers a high dose of radiation to vertebral metastases and can sometimes lead to a vertebral compression fracture. Using body cement on the largest part of the vertebra (a procedure called vertebral body cement augmentation) may help prevent a fracture after stereotactic spinal radiosurgery. It may also lessen pain and improve quality of life in patients with solid tumors and spinal metastases undergoing this surgery.

Detailed Description: PRIMARY OBJECTIVES: I. To assess whether prophylactic cement augmentation reduces new or progressive vertebral body fracture at 3 months in high risk patients undergoing single fraction spine stereotactic radiosurgery. SECONDARY OBJECTIVES: I. To assess the impact of prophylactic cement augmentation on time to first new or progressive vertebral body fracture. II. To assess the impact of prophylactic cement augmentation on pain control measured every three months post treatment. III. To assess the impact of prophylactic cement augmentation on quality of life measured every three months post treatment. IV. To estimate local control in each arm. V. To estimate overall survival in each arm. VI. To document and assess post-treatment adverse side effects between the two arms. VI. To document and assess the relationship between radiographic vertebral body fracture, pain control and quality of life. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients undergo stereotactic spinal radiosurgery per standard of care. ARM II: Patients undergo vertebral body cement augmentation within 4 weeks before or after standard stereotactic spinal radiosurgery. After completion of study treatment, patients are followed up every 3 months for 2 years.